As the first effective vascular targeting drug for the monotherapy of advanced NSCLC, anlotinib targets include VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β. The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.